Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

Abstract Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have add...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Ruijuan Du, Nan Xiao, Li Han, KeLei Guo, Kai Li, Zhiguo Chen, Hui Zhang, Zijun Zhou, Yunlong Huang, Xulin Zhao, Hua Bian
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Nature Portfolio 2024-04-01
Cyfres:Scientific Reports
Pynciau:
ESCC
Dexrazoxane
SDCBP/MDA-9/syntenin
EGFR
Cancer treatment
Mynediad Ar-lein:https://doi.org/10.1038/s41598-024-59665-5

Rhyngrwyd

https://doi.org/10.1038/s41598-024-59665-5

Eitemau Tebyg